Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBITDA Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EBITDA Margin for 5 consecutive years, with 234.98% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 400466.0% to 234.98% in Q3 2025 year-over-year; TTM through Dec 2025 was 1114.72%, a 47724.0% decrease, with the full-year FY2025 number at 1114.72%, down 47724.0% from a year prior.
  • EBITDA Margin was 234.98% for Q3 2025 at Janux Therapeutics, up from 4239.64% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 79.25% in Q2 2024 to a low of 4239.64% in Q3 2024.
  • A 5-year average of 1000.5% and a median of 831.01% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -377547bps in 2024, then soared 400466bps in 2025.
  • Janux Therapeutics' EBITDA Margin stood at 848.39% in 2021, then skyrocketed by 37bps to 538.59% in 2022, then grew by 25bps to 403.01% in 2023, then tumbled by -952bps to 4239.64% in 2024, then skyrocketed by 94bps to 234.98% in 2025.
  • Per Business Quant, the three most recent readings for JANX's EBITDA Margin are 234.98% (Q3 2025), 4239.64% (Q3 2024), and 79.25% (Q2 2024).